HSPA14 Antibody

What is HSPA14 and what cellular functions is it involved in?

HSPA14 (heat shock 70kDa protein 14) is a member of the heat shock protein 70 family with an observed molecular weight of approximately 55 kDa. Current research indicates it may function as a transcriptional regulator, particularly in viral replication contexts. Studies have demonstrated that HSPA14 interacts with HspBP1, a known inhibitor of HIV-1 replication, suggesting its involvement in antiviral cellular responses. HSPA14 appears to participate in protein-protein interactions that affect transcriptional regulation, particularly in the context of viral infections .

What sample types have been validated for HSPA14 antibody applications?

The HSPA14 antibody (28503-1-AP) has been validated for human samples across multiple cell lines and tissue types. Positive Western blot detection has been confirmed in HEK-293 cells, HeLa cells, and K-562 cells. For immunohistochemistry applications, the antibody has shown positive detection in human ovary cancer tissue. Immunofluorescence/ICC applications have been validated in K-562 cells. The antibody has demonstrated specific reactivity with human samples, making it suitable for research involving human-derived materials .

What are the recommended experimental conditions for HSPA14 antibody applications?

For Western blot applications, the recommended dilution range is 1:500-1:2000. For immunohistochemistry, dilutions between 1:50-1:500 are suggested, with antigen retrieval preferably performed using TE buffer pH 9.0 (alternatively, citrate buffer pH 6.0 can be used). For immunofluorescence/ICC applications, dilutions between 1:50-1:500 are recommended. The antibody should be stored at -20°C and remains stable for one year after shipment. For 20μl preparations, the product contains 0.1% BSA. It's important to note that optimal dilutions may be sample-dependent, and researchers should titrate the antibody in each testing system to obtain optimal results .

How should Western blot protocols be optimized when using HSPA14 antibody?

When optimizing Western blot protocols for HSPA14 antibody, researchers should consider the following methodological approach:

• Protein extraction: Use RIPA lysis buffer with protease inhibitor for total cellular protein extraction

• Protein quantification: Employ BCA Protein Assay for accurate concentration determination

• Gel selection: Use 10% polyacrylamide gels for optimal separation of the 55 kDa HSPA14 protein

• Transfer: Transfer proteins to PVDF membranes using semi-dry transfer systems

• Blocking: Block membranes with either 5% skim dried milk or BSA

• Primary antibody: Apply HSPA14 antibody at 1:500-1:2000 dilution

• Detection: Use ECL chemiluminescent substrate for visualization

• Controls: Include positive controls (HEK-293, HeLa, or K-562 cell lysates)

For viral infection studies, comparison of HSPA14 expression between infected and uninfected cells has demonstrated consistent downregulation patterns, suggesting that standardized loading controls are essential for accurate interpretation .

What considerations are important when designing co-immunoprecipitation experiments with HSPA14 antibody?

When designing co-immunoprecipitation (Co-IP) experiments with HSPA14 antibody to investigate protein-protein interactions, researchers should consider these key methodological factors:

• Lysate preparation: Total cell proteins should be extracted under non-denaturing conditions to preserve protein-protein interactions

• Antibody selection: Both HSPA14 and target protein (e.g., HspBP1) antibodies should be validated for IP applications

• IP protocol: Incubate total proteins with HSPA14 or interacting protein antibodies

• Pull-down method: Use magnetic beads (as demonstrated with the Classic Magnetic IP/Co-IP Kit) for efficient complex isolation

• Controls: Include appropriate negative controls (IgG of the same species) and input samples

• Reciprocal confirmation: Perform reciprocal Co-IP (pull down with anti-HSPA14 and probe for interacting protein, then reverse) to confirm interactions

• Detection: Follow with immunoblotting to identify complexes

Research has successfully demonstrated HSPA14 interaction with HspBP1 using this approach in both cell lines and primary cells isolated from patients .

What are the optimal approaches for evaluating HSPA14 expression at transcript and protein levels?

For comprehensive evaluation of HSPA14 expression, researchers should employ both transcript and protein analysis using the following methodological approaches:

For transcript analysis (qRT-PCR):

• RNA extraction: Extract total RNA from target cells/tissues using standard methods

• cDNA synthesis: Perform reverse transcription with oligo(dT) primers

• qPCR design: Use validated HSPA14-specific primers

• Reference genes: Include appropriate housekeeping genes (e.g., β-actin) for normalization

• Data analysis: Calculate fold change using the 2^(-ΔΔCT) method where:

  • ΔCT = CT(HSPA14) – CT(β-actin)

  • ΔΔCT = ΔCT(treated) – ΔCT(control)

For protein analysis (Western blot):

• Protein extraction and quantification as described previously

• Equal loading: Ensure equal amounts of protein across samples

• Gel electrophoresis: Use appropriate percentage gels for the 55 kDa HSPA14 protein

• Transfer and immunoblotting with optimized HSPA14 antibody dilutions

• Densitometry: Quantify bands using image analysis software and normalize to loading controls

This dual approach has successfully demonstrated HSPA14 downregulation in HIV-infected cells at both transcript and protein levels in multiple cell types, including Jurkat cells, CEM cells, and primary CD4+ T cells .

How can HSPA14 overexpression and knockdown systems be established for functional studies?

Establishing reliable HSPA14 overexpression and knockdown systems for functional studies requires careful design and validation:

For HSPA14 overexpression:

• Vector selection: Use appropriate expression vectors (e.g., GV657 vector as reported)

• Cloning: Clone the full HSPA14 coding sequence into the expression vector

• Verification: Sequence-verify the construct

• Packaging: Co-transfect the HSPA14 vector with packaging plasmids into HEK293T cells using lipofection (e.g., Lipo3000)

• Virus harvest: Collect virus 48-72 hours post-transfection

• Concentration: Concentrate virus using PEG8000 precipitation

• Titer determination: Quantify viral particles

• Transduction: Infect target cells with the lentivirus

• Selection: Apply appropriate selection if needed

• Validation: Confirm HSPA14 overexpression by qRT-PCR and Western blot

For HSPA14 knockdown:

• shRNA design: Design specific short hairpin RNAs targeting HSPA14 (GV493 vector has been used successfully)

• Transfection: Transfect target cells at 50% confluency

• Medium change: Replace medium after 4 hours with DMEM containing 10% FBS

• Cell collection: Harvest cells 48 hours post-transfection

• Validation: Confirm knockdown efficiency by qRT-PCR and Western blot

For both approaches, appropriate controls should be included: vector-only controls (GV657 or GV493 vectors) and untransfected cells as blank controls. This methodology has successfully demonstrated that HSPA14 overexpression inhibits HIV replication while knockdown promotes viral replication in a dose-dependent manner .

What technical considerations are important when investigating HSPA14 interactions with other proteins?

Investigating HSPA14 protein-protein interactions requires sophisticated technical approaches:

• Prediction tools: Use bioinformatics to predict potential interacting partners based on structure and function

• Co-immunoprecipitation: As detailed previously, use antibodies against HSPA14 or potential partners (e.g., HspBP1)

• Validation in multiple systems: Confirm interactions in relevant cell lines and primary cells

• Recombinant protein studies: Use purified proteins for direct binding assays

• Domain mapping: Create deletion mutants to identify interaction domains

• Functional validation: Assess the impact of disrupting interactions on cellular processes

• Visualization: Consider proximity ligation assays or fluorescence colocalization studies

• Controls: Include appropriate negative controls to confirm specificity

Research has successfully used co-immunoprecipitation to demonstrate that HSPA14 interacts with HspBP1 in both HIV-infected CEM cells and CD4+ T cells isolated from acute HIV-infected patients. This interaction appears functionally significant as both proteins have been implicated in HIV replication control .

How can researchers determine if HSPA14 expression changes are cause or consequence in disease models?

Determining causality in HSPA14 expression changes in disease models requires rigorous experimental approaches:

• Temporal studies: Establish detailed time-course experiments to determine whether HSPA14 changes precede or follow disease markers

• Gain/loss of function: Use the previously described overexpression and knockdown systems to manipulate HSPA14 levels and observe effects on disease progression

• Dose-response relationships: Establish whether effects are proportional to HSPA14 levels

• Rescue experiments: Determine if restoring HSPA14 levels can reverse disease phenotypes

• Mechanistic validation: Identify and validate molecular pathways connecting HSPA14 to disease phenotypes

• In vivo confirmation: Validate findings from in vitro studies in appropriate animal models or patient samples

In HIV infection research, evidence suggests a causal role for HSPA14 in controlling viral replication. Time-course studies showed that HIV infection downregulates HSPA14, while modulating HSPA14 levels directly affected viral replication in a dose-dependent manner. Additionally, comparison of patients with high viral load (HVL) versus low viral load (LVL) showed differential HSPA14 expression, providing in vivo support for causality .

How can HSPA14 antibody be utilized in viral infection research?

HSPA14 antibody can be strategically applied in viral infection research through multiple methodological approaches:

• Expression profiling: Monitor HSPA14 protein levels before and after viral infection using Western blot

• Cellular localization: Employ immunofluorescence to track HSPA14 localization changes during infection

• Interaction studies: Use co-immunoprecipitation to identify virus-induced changes in HSPA14 protein complexes

• Tissue analysis: Apply immunohistochemistry to examine HSPA14 expression in infected tissues

• Functional correlation: Correlate HSPA14 levels with viral replication markers

• Comparative analysis: Compare HSPA14 expression across patient groups with different disease progression profiles

Research has demonstrated that HSPA14 expression is downregulated following HIV infection in multiple cell types, and HSPA14 levels inversely correlate with HIV replication. The HSPA14 antibody has been successfully used to detect protein-protein interactions with HspBP1, a known HIV transcriptional inhibitor, providing insights into potential antiviral mechanisms .

What insights has HSPA14 research provided about host-pathogen interactions?

HSPA14 research has revealed several important insights about host-pathogen interactions:

• Viral counteraction strategies: HIV-1 appears to specifically downregulate HSPA14 expression in infected cells, suggesting the virus has evolved mechanisms to counteract HSPA14's antiviral properties

• Transcriptional regulation: HSPA14 may inhibit HIV-1 replication through transcriptional regulation, potentially by:

  • Direct interaction with HIV-1 LTR cis-acting elements

  • Suppression of transcriptional regulators that promote viral replication

• Protein-protein interactions: HSPA14 interacts with HspBP1, which competes with NF-κB for binding to HIV-1 LTR promoter

• Differential expression patterns: In acute HIV infection, patients with low viral loads (LVL) show higher HSPA14 expression than those with high viral loads (HVL)

• Coordinated host response: HSPA14 functions within a network of heat shock proteins that collectively respond to viral infection

These findings suggest that HSPA14 is part of the host's intrinsic antiviral defense system, and its expression levels may influence disease progression in HIV-infected individuals .

How does HSPA14 expression correlate with clinical parameters in disease studies?

Research on the correlation between HSPA14 expression and clinical parameters has revealed significant patterns:

In studies of acute HIV infection patients, CD4+ T cells from patients with low viral loads (LVL) exhibited significantly higher HSPA14 expression at both transcript and protein levels compared to patients with high viral loads (HVL). This correlation remained consistent even when patients had similar general status but different HIV RNA levels, suggesting HSPA14 expression may be a marker of viral control rather than simply a consequence of disease status. This pattern was validated through both qRT-PCR and Western blot analyses with densitometry quantification, confirming statistical significance (p ≤ 0.001) .

What are common technical challenges when using HSPA14 antibody and how can they be addressed?

Researchers may encounter several technical challenges when working with HSPA14 antibody, each requiring specific troubleshooting approaches:

Additionally, for specific applications like immunofluorescence/ICC, where detection in K-562 cells has been validated, using the recommended dilution range (1:50-1:500) and following established protocols is crucial for reproducible results .

How can researchers validate HSPA14 antibody specificity for their particular application?

Validating HSPA14 antibody specificity requires a systematic approach:

• Positive controls: Include known HSPA14-expressing samples (HEK-293, HeLa, or K-562 cells have been validated)

• Negative controls: Use cell lines or tissues with minimal HSPA14 expression

• Knockdown validation: Compare antibody signal between HSPA14 knockdown and control cells

• Overexpression validation: Compare antibody signal between HSPA14 overexpressing and control cells

• Peptide competition: Pre-incubate antibody with blocking peptide to confirm specificity

• Cross-validation: Compare results using alternative HSPA14 antibodies targeting different epitopes

• Multiple detection methods: Confirm findings using complementary techniques (e.g., IF/ICC to confirm WB results)

• Expected molecular weight: Confirm detection at the expected 55 kDa size

Research has successfully validated HSPA14 antibody specificity by demonstrating consistent detection of the protein in multiple cell types, with expected changes in signal following overexpression or knockdown manipulations. The antibody (28503-1-AP) has been specifically validated for human samples and shown to be effective in detecting HSPA14 in Western blot, immunohistochemistry, and immunofluorescence applications .

What considerations are important when analyzing HSPA14 expression data across different experimental conditions?

When analyzing HSPA14 expression data across different experimental conditions, researchers should consider several methodological factors:

• Normalization strategy:

  • For qRT-PCR: Use consistent reference genes (e.g., β-actin) and apply the 2^(-ΔΔCT) method

  • For Western blot: Normalize to loading controls and use densitometry for quantification

• Statistical analysis:

  • For continuous data: Apply Student's t-test for comparisons between two groups

  • For categorical data: Use chi-square test

  • Consider significance threshold (p < 0.05) for determining meaningful differences

• Biological replicates:

  • Include at least three biological replicates for all experiments

  • Report results as mean ± standard deviation (x̄ ± s)

• Technical considerations:

  • Account for batch effects across experiments

  • Ensure consistent experimental conditions (cell density, passage number, etc.)

  • Consider time-dependent changes in expression

• Comparative analysis:

  • When comparing patient groups (e.g., HVL vs. LVL), ensure groups are well-matched for confounding variables

  • Consider analyzing multiple HSPA isoforms (HSPA2, HSPA5, HSPA6, etc.) for comprehensive understanding

Research has demonstrated the importance of these considerations by showing significant differences in HSPA14 expression between patient groups with different viral loads, validating findings through multiple technical approaches, and ensuring statistical rigor through appropriate replication and analysis methods .